Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Intensive Care Medicine
Published in: Intensive Care Medicine 10/2016

01-10-2016 | Editorial

Beta-blockers in septic shock to optimize hemodynamics? Yes

Authors: Daniel A. Reuter, James A. Russell, Armand Mekontso Dessap

Published in: Intensive Care Medicine | Issue 10/2016

Login to get access

Excerpt

Septic shock represents one of the maximum physical stresses to the organism. The physiological response to stress includes increased release of catecholamines, leading to a stimulation of cardiac β1-adrenergic receptors thereby increasing heart rate and ventricular contractility in order to increase global and microvascular blood flow and oxygen delivery to vital organs. Yet there are adverse effects of adrenergic stimulation including tachyarrhythmias, increased cardiac oxygen consumption with risk of cardiac ischemia, and immune dysregulation. So while it sounds at first contradictory to stabilize the cardiovascular function by giving β-blocking agents to “brake” the system, there could be benefits. However, is beta-blockade in these clinical circumstances really a brake? …
Literature
1.
Morelli A, Singer M, Raieri VM, D’Egidio A, Mascia L, Orecchioni A et al (2016) Heart rate reduction with esmolol is associated with improved arterial elastance in patients with septic shock: a prospective observational study. Intensive Care Med. doi:10.​1007/​s00134-016-4351-2
2.
Packer M, Fowler MB, Roecker EB et al (2002) Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106:2194–2199CrossRefPubMed
3.
Dellinger RP, Levy MM, Rhodes A et al (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228CrossRefPubMed
4.
Cecconi M, De Backer D, Antonelli M et al (2014) Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med 40:1795–1815CrossRefPubMedPubMedCentral
5.
Boyd JH, Forbes J, Nakada TA, Walley KR, Russell JA (2011) Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med 39:259–265CrossRefPubMed
6.
Wang Z, Wu Q, Nie X, Guo J, Yang C (2015) Combination therapy with milrinone and esmolol for heart protection in patients with severe sepsis: a prospective, randomized trial. Clin Drug Investig 35:707–716CrossRefPubMed
7.
Sanfilippo F, Santonocito C, Morelli A, Foex P (2015) Beta-blocker use in severe sepsis and septic shock: a systematic review. Curr Med Res Opin 31:1817–1825CrossRefPubMed
8.
Morelli A, Ertmer C, Westphal M et al (2013) Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA 310:1683–1691CrossRefPubMed
9.
Macchia A, Romero M, Comignani PD et al (2012) Previous prescription of β-blockers is associated with reduced mortality among patients hospitalized in intensive care units for sepsis. Crit Care Med 40:2768–2772CrossRefPubMed
10.
Morelli A, Donati A, Ertmer C, Rehberg S, Kampmeier T, Orecchioni A, D’Egidio A, Cecchini V, Landoni G, Pietropaoli P, Westphal M, Venditti M, Mebazaa A, Singer M (2013) Microvascular effects of heart rate control with esmolol in patients with septic shock: a pilot study. Crit Care Med 41:2162–2168CrossRefPubMed
11.
Kimmoun A, Louis H, Al Kattani N et al (2015) β1-adrenergic inhibition improves cardiac and vascular function in experimental septic shock. Crit Care Med 43:e332–e340CrossRefPubMed
12.
Dimopoulos G, Theodorakopoulou M, Armaganidis A et al (2015) Esmolol: immunomodulator in pyelonephritis by Pseudomonas aeruginosa. J Surg Res 198:175–184CrossRefPubMed
13.
Ibrahim-Zada I, Rhee P, Gomez CT, Weller J, Friese RS (2014) Inhibition of sepsis-induced inflammatory response by β1-adrenergic antagonists. J Trauma Acute Care Surg 76:320–327CrossRefPubMed
14.
Wang Z, Wu Q, Nie X, Guo J, Yang C (2016) Infusion of esmolol attenuates lipopolysaccharide-induced myocardial dysfunction. J Surg Res 200:283–289CrossRefPubMed
Metadata
Title
Beta-blockers in septic shock to optimize hemodynamics? Yes
Authors
Daniel A. Reuter
James A. Russell
Armand Mekontso Dessap
Publication date
01-10-2016
Publisher
Springer Berlin Heidelberg
Published in
Intensive Care Medicine / Issue 10/2016
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-016-4414-4

Other articles of this Issue 10/2016

Intensive Care Medicine 10/2016 Go to the issue

Correspondence

Ave CAESAR: at the end of life in the intensive care unit

Editorial

Beta-blockers in septic shock to optimize hemodynamics? No

Letter

Elevated soluble IL-7 receptor concentration in non-survivor ICU patients

Editorial

Continuous infusion of β-lactam antibiotics for all critically ill patients?

Correspondence

Antibiotic de-escalation: observational causal inference and culture dependence

Editorial

Assessment of oxygenation response to prone position ventilation in ARDS by lung ultrasonography